Search bioRxivSearch

Biology subjects

Ingber, D. E.

Publications and source records attributed to Ingber, D. E..

2 recordsLinked to original sources

Complex human gut microbiome cultured in anaerobic human intestine chips

The diverse bacterial populations that comprise the commensal microbiota of the human intestine play a central role in health and disease, yet no method is available to sustain these complex microbial communities in direct contact with living human intestinal cells and their overlying mucus layer in vitro. Here we describe a human Organ-on-a-Chip (Organ Chip) microfluidic platform that permits control and real-time assessment of physiologically-relevant oxygen gradients, and which enables co-culture of living human intestinal epithelium with stable communities of aerobic and anaerobic human gut microbiota. When compared to aerobic co-culture conditions, establishment of a transluminal hypoxia gradient sustained higher microbial diversity with over 200 unique operational taxonomic units (OTUs) from 11 different genera, and an abundance of obligate anaerobic bacteria with ratios of Firmicutes and Bacteroidetes similar to those observed in human feces, in addition to increasing intestinal barrier function. The ability to culture human intestinal epithelium overlaid by complex human gut microbial communities within microfluidic Intestine Chips may enable investigations of host-microbiome interactions that were not possible previously, and serve as a discovery tool for development of new microbiome-related therapeutics, probiotics, and nutraceuticals.

bioengineering

Broad spectrum capture of clinical pathogens using engineered Fc-Mannose-Binding Lectin (FcMBL) enhanced by antibiotic treatment

FcMBL, an engineered version of the blood opsonin mannose-binding lectin (MBL) that contains the carbohydrate recognition domain (CRD) and flexible neck regions of MBL fused to the Fc portion of human IgG1, has been shown to bind various microbes and pathogen-associated molecular patterns (PAMPs). FcMBL also has been used to create an enzyme-linked lectin sorbent assay (ELLecSA) for use as a rapid (< 1 hr) diagnostic of bloodstream infections. Here we extended this work by using the ELLecSA to test FcMBLs ability to bind to more than 200 different isolates from over 100 different pathogen species. FcMBL bound to 86% of the isolates and 110 of the 122 (90%) different pathogen species tested, including bacteria, fungi, viruses, and parasites. It also bound to PAMPs including, lipopolysaccharide endotoxin (LPS) and lipoteichoic acid (LTA) from Gram-negative and Gram-positive bacteria, as well as lipoarabinomannan (LAM) and phosphatidylinositol mannoside 6 (PIM6) from Mycobacterium tuberculosis. The efficiency of pathogen detection and variation between binding of different strains of the same species also could be improved by treating the bacteria with antibiotics prior to FcMBL capture to reveal previously concealed binding sites within the bacterial cell wall. As FcMBL can bind to pathogens and PAMPs in urine as well as blood, its broad-binding capability could be leveraged to develop a variety of clinically relevant technologies, including infectious disease diagnostics, therapeutics, and vaccines.

immunology